Quick Answer
NUTRA PHARMA CORP reported Total Revenue of $246.3 thousand for fiscal year 2024.
NUTRA PHARMA CORP — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $246.3K +19.8% |
$205.6K +41.0% |
$145.8K +49.2% |
$97.7K +88.3% |
$51.9K -50.3% |
$104.4K -20.1% |
| Revenue (ASC 606) | $246.3K +19.8% |
$205.6K +41.0% |
$145.8K +49.2% |
$97.7K +88.3% |
$51.9K -50.3% |
$104.4K -20.1% |
| Net Income | -$1.29M +7.7% |
-$1.39M -117.0% |
$8.18M +162.4% |
-$13.10M -1602.5% |
-$769.2K +88.3% |
-$6.59M -69.7% |
| Diluted EPS | $0.00 | $0.00 | $0.00 +100.0% |
-$0.00 | — | — |
| Total Assets | $599.5K -6.4% |
$640.4K -15.2% |
$754.9K -3.2% |
$780.0K +158.5% |
$301.8K -11.2% |
$339.8K +140.3% |
| Cash and Equivalents | — | — | — | — | — | — |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | -$14.81M -7.6% |
-$13.77M -11.2% |
-$12.38M +40.7% |
-$20.88M -81.6% |
-$11.49M +1.8% |
-$11.70M -97.1% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$878.4K +1.0% |
-$887.0K +53.5% |
-$1.91M +4.1% |
-$1.99M -115.0% |
-$924.9K +24.8% |
-$1.23M +34.5% |
| Gross Profit | $247.3K -37.6% |
$396.5K +59.2% |
$249.0K +2841.1% |
$8.5K -43.2% |
$14.9K -57.0% |
$34.7K +146.9% |
| Shares Outstanding | 7.10B +0.5% |
7.06B +0.4% |
7.04B +3.9% |
6.77B -2.6% |
6.96B +18.4% |
5.88B +45.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $84.5K | +63.5% | +12.7% |
| Revenue (ASC 606) | June 30, 2025 | $84.5K | +63.5% | +12.7% |
| Net Income | June 30, 2025 | $369.6K | +200.7% | +241.8% |
| Diluted EPS | June 30, 2025 | $0.00 | — | — |
| Total Assets | June 30, 2025 | $859.1K | +36.2% | +43.3% |
| Cash and Equivalents | September 30, 2014 | $27.8K | +9.0% | -36.8% |
| Long-Term Debt | March 31, 2025 | $9.06M | — | +5.0% |
| Stockholders Equity | June 30, 2025 | -$15.83M | -8.8% | +2.3% |
| R&D Expense | September 30, 2011 | $17.3K | -1.7% | -71.9% |
| Operating Income | June 30, 2025 | -$290.5K | -32.4% | -57.3% |
| Gross Profit | June 30, 2025 | $75.6K | +37.9% | +7.0% |
| Shares Outstanding | June 30, 2025 | 7.10B | +0.0% | +0.0% |
- NUTRA PHARMA CORP reported Total Revenue of $246.3 thousand for fiscal year 2024.
- NUTRA PHARMA CORP showed an increase of +19.8% in Total Revenue compared to the prior fiscal year.
- NUTRA PHARMA CORP reported Revenue (ASC 606) of $246.3 thousand for fiscal year 2024.
- NUTRA PHARMA CORP showed an increase of +19.8% in Revenue (ASC 606) compared to the prior fiscal year.
- NUTRA PHARMA CORP reported Net Income of -$1.29 million for fiscal year 2024.
- NUTRA PHARMA CORP showed an increase of +7.7% in Net Income compared to the prior fiscal year.
- NUTRA PHARMA CORP reported Diluted EPS of $0.00 per share for fiscal year 2024.
- NUTRA PHARMA CORP reported Total Assets of $599.5 thousand for fiscal year 2024.
- NUTRA PHARMA CORP showed a decrease of -6.4% in Total Assets compared to the prior fiscal year.
- NUTRA PHARMA CORP reported Cash and Equivalents of $15.5 thousand for fiscal year 2014.
- NUTRA PHARMA CORP showed an increase of +234.7% in Cash and Equivalents compared to the prior fiscal year.
- NUTRA PHARMA CORP reported Long-Term Debt of $51.4 thousand for fiscal year 2018.
- NUTRA PHARMA CORP reported Stockholders Equity of -$14.81 million for fiscal year 2024.
- NUTRA PHARMA CORP showed a decrease of -7.6% in Stockholders Equity compared to the prior fiscal year.
- NUTRA PHARMA CORP reported R&D Expense of $3.0 thousand for fiscal year 2012.
- NUTRA PHARMA CORP showed a decrease of -96.6% in R&D Expense compared to the prior fiscal year.
- NUTRA PHARMA CORP reported Operating Income of -$878.4 thousand for fiscal year 2024.
- NUTRA PHARMA CORP showed an increase of +1.0% in Operating Income compared to the prior fiscal year.
- NUTRA PHARMA CORP reported Gross Profit of $247.3 thousand for fiscal year 2024.
- NUTRA PHARMA CORP showed a decrease of -37.6% in Gross Profit compared to the prior fiscal year.
- NUTRA PHARMA CORP reported Shares Outstanding of 7.10 billion shares for fiscal year 2024.
- NUTRA PHARMA CORP showed an increase of +0.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: